ALEXANDRIA, Va. – The Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) has received a second $1 million from Susan G. Komen® toward the development of CancerLinQ™, a big data project that aims to rapidly improve the overall quality of cancer care. This donation builds on Komen’s previous support of this initiative.
“We are grateful for Susan G. Komen’s continued support of CancerLinQ,” said Allen S. Lichter, MD, ASCO Chief Executive Officer and Chair of CancerLinQ LLC’s Board of Governors. “This donation will allow us to add more capabilities to the CancerLinQ system, thereby helping to improve the quality of care for people living with cancer.”
CancerLinQ is a powerful database made up of vast amounts of usable, searchable, real-world cancer information. This national initiative will allow users to see trends among millions of patients by analyzing cancer patient medical records, uncovering patterns that can improve patient care, and enabling doctors to compare their care against that of their peers and recommended guidelines.
The new funding from Komen will support system components and professional expertise to include breast cancer clinical decision support, a patient portal customized for patients with breast cancer, and the development of breast cancer specific guidelines and measures. In November 2012, Komen supported CancerLinQ with $1 million for a breast cancer-specific prototype that held 170,000 de-identified patient records.
“As one of the first supporters of this initiative, Susan G. Komen recognized early on the potential of this rapid learning system in oncology to facilitate greater communication and collaboration among healthcare professionals and improve the quality of patient care and push progress in clinical research,” said Komen President and CEO Judy Salerno, M.D., M.S. “We are pleased to continue our support of CancerLinQ.”
CancerLinQ is supported in part through the Conquer Cancer Foundation, whose generous donors have helped make the system possible. Major supporters in addition to Komen include Amgen; Astellas; AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Cancer Treatment Centers of America®; Chan Soon-Shiong Family Foundation; Genentech BioOncology™; HELSINN; Lilly; Raj Mantena, RPh; Novartis Oncology; Pfizer Oncology; and Thomas G. Roberts, Jr., MD, and Susan M. DaSilva.
CancerLinQ is a project of CancerLinQ LLC. For more information, please visit CancerlinQ.org.
Founded in 1964, the American Society of Clinical Oncology (ASCO) is the world’s leading professional organization representing physicians who care for people with cancer. With more than 35,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation, which funds groundbreaking research and programs that make a tangible difference in the lives of people with cancer. For ASCO information and resources, visit asco.org. Patient-oriented cancer information is available at Cancer.Net.